Fishing for anti-leishmania drugs: Principles and problems

Advances in Experimental Medicine and Biology

Volumn 625, Issue , 2008, Pages 48-60

  Handman, Emanuela ^a   Kedzierski, Lukasz ^b   Uboldi, Alessandro D ^b   Goding, James W ^b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; AMINOGLYCOSIDE DERIVATIVE; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; BETA LACTAM ANTIBIOTIC; CADABACINE; CHIMANINE A; CHIMANINE D; CHLORAMPHENICOL; GLYCOPEPTIDE; IMIQUIMOD; INTERLEUKIN 10; LICOCHALCONE A; LUNARINE; MACROLIDE; MEGLUMINE ANTIMONATE; MITOCHONDRIAL PROTEIN; MONOCLONAL ANTIBODY; NATURAL PRODUCT; OXAZOLIDINONE DERIVATIVE; PAROMOMYCIN; PENTAMIDINE; PLANT EXTRACT; QUINOLONE DERIVATIVE; SITAMAQUINE; STIBOGLUCONATE SODIUM; STREPTOGRAMIN; SULFANILAMIDE DERIVATIVE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DISABILITY ADJUSTED LIFE YEARS; DISABILITY SEVERITY; DRUG COST; DRUG DESIGN; DRUG EFFECT; DRUG TARGETING; GALIPEA LONGIFLORA; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTHERMIC THERAPY; IN VIVO STUDY; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS; MEDICINAL PLANT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARASITE TRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PSYCHODIDAE; RADIOFREQUENCY RADIATION; REVIEW; SEQUENCE HOMOLOGY; SPECIES IDENTIFICATION; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; VACCINE PRODUCTION; VECTOR CONTROL; X RAY CRYSTALLOGRAPHY;

ANIMALIA; LEISHMANIA INFANTUM; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

EID: 84934438184     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-77570-8_5     Document Type: Review

References (102)

1. Barrett JF. Can biotech deliver new antibiotics? Curr Opin Microbiol 2005; 8(5):498-503.
2. Greenfield RA, Bronze MS. Current therapy and the development of therapeutic options for the treatment of diseases due to bacterial agents of potential biowarfare and bioterrorism. Curr Opin Investig Drugs 2004; 5(2):135-40.
3. North CS, Pollio DE, Pfefferbaum B et al. Capitol hill staff workers' experiences of bioterrorism: Qualitative findings from focus groups. J Trauma Stress 2005; 18(1):79-88.
4. Hotez PJ, Molyneux DH, Fenwick A et al. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, Tuberculosis, and Malaria. PLoS Med 2006; 3(5):e102.
5. Murray HW, Berman JD, Davies CR et al. Advances in leishmaniasis. Lancet 2005; 366(9496):1561-77.
6. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005; 21(11):508-12.
7. Davis AJ, Kedzierski L. Recent advances in antileishmanial drug development. Curr Opin Investig Drugs 2005; 6(2): 163-9.
8. Ouellette M, Borst P. Drug resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania. Res Microbiol 1991; 142(6):737-46.
9. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19(11):502-8.
10. Herrling P. Experiments in social responsibility. Nature 2006; 439:267-268.
11. Ashford RW. The leishmaniases as emerging and reemerging zoonoses. Int J Parasitology 2000; 30:1269-1281.
12. Reithinger R, Mohsen M, Aadil K et al. Anthroponotic cutaneous leishmaniasis, Kabul, Afghanistan. Emerg Infect Dis 2003; 9(6):727-9.
13. Seaman J, Mercer AJ, Sondorp HE et al. Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996; 124(7):664-72.
14. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27(5):305-18.
15. Korzeniewski K, Olszanski R. Leishmaniasis among soldiers of stabilization forces in Iraq. Review article. Int Marit Health 2004; 55(1-4):155-63.
16. Weina PJ, Neafie RC, Wortmann G et al. Old world leishmaniasis: An emerging infection among deployed US military and civilian workers. Clin Infect Dis 2004; 39(11):1674-80.
17. Chevalier B, Carmoi T, Sagui E et al. Report of the first cases of cutaneous leishmaniasis in East Timor. Clin Infect Dis 2000; 30:840.
18. Rose K, Curtis J, Baldwin T et al. Cutaneous leishmaniasis in red kangaroos: Isolation and characterization of the causative organisms. Int J Parasitol 2004; 34:655-664.
19. Desjeux P. Leishmaniasis. Nature Reviews Microbiology 2004; 2:692-693.
20. WHO/CTD. Leishmaniasis control. Burden and trends 1998:1-4.
21. Herwaldt BL. Leishmaniasis. Lancet 1999; 354:1191-1199.
22. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13(4):243-8.
23. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97(Suppl 1):135-42.
24. Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: Can schistosomiasis control benefit from an integrated approach? Trends Parasitol 2005; 21(3):112-7.
25. Bates PA, Rogers ME. New insights into the developmental biology and transmission mechanisms of Leishmania. Curr Mol Med 2004; 4(6):601-9.
26. Kamhawi S, Ramalho-Ortigao M, Pham VM et al. A role for insect galectins in parasite survival. Cell 2004; 119(3):329-41.
27. Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv Parasitol 2005; 59:1-75.
28. Anderson CF, Mendez S, Sacks DL. Nonhealing infection despite Thl polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol 2005; 174:2934-2941.
29. Jacobson RL. Leishmania tropica (Kinetoplastida: Trypanosomatidae)-a perplexing parasite. Folia Parasitol (Praha) 2003; 50(4):241-50.
30. Bosque F, Saravia NG, Valderrama L et al. Distinct innate and acquired immune responses to Leishmania in putative susceptible and resistant human populations endemically exposed to L. (Viannia) panamensis infection. Scand J Immunol 2000; 51(5):533-41.
31. le Fichoux Y, Quaranta JF, Aufeuvre JP et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 1999; 37(6):1953-7.
32. Riera C, Fisa R, Udina M et al. Detection of Leishmania infantum cryptic infection in asymptomatic blood donors living in an endemic area (Eivissa, Balearic Islands, Spain) by different diagnostic methods. Trans R Soc Trop Med Hyg 2004; 98(2):102-10.
33. BlackweU JM, Mohamed HS, Ibrahim ME. Genetics and visceral leishmaniasis in the Sudan: Seeking a link. Trends Parasitol 2004; 20(6):268-74.
34. Follador I, Araujo C, Bacellar O et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 2002; 34(11):E54-8.
35. Davies CR, Kaye P, Croft SL et al. Leishmaniasis: New approaches to disease control. Bmj 2003; 326(7385):377-82.
36. Blum J, Desjeux P, Schwartz E et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004; 53(2):158-166.
37. Bourreau E, Prevot G, Gardon J et al. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J Infect Dis 2001; 184(12):1628-30.
38. Murray HW. Prevention of relapse after chemotherapy in a chronic intracellular infection: Mechanisms in experimental visceral leishmaniasis. J Immunol 2005; 174(8):4916-23.
39. Convit J, Castellanos PL, Rondon A et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987; 1(8530):401-5.
40. Convit J, Castellanos PL, Ulrich Met al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J Infect Dis 1989; 160(1):104-115.
41. Arevalo I, Ward B, Miller R et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33(11):1847-51.
42. Reithinger R, Mohsen M, Wahid Met al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: A randomized, controlled trial. Clin Infect Dis 2005; 40(8):1148-55.
43. Reithinger R, Aadil K, Kolaczinski Jet al. Social impact of leishmaniasis, Afghanistan. Emerg Infect Dis 2005; 11(4):634-6.
44. Drews J. Drug discovery: A historical perspective. Science 2000; 287(5460):1960-4.
45. Bleicher KH, Bohm HJ, Muller K et al. Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Discov 2003; 2(5):369-78.
46. Bleicher KH, Green LG, Martin RE et al. Ligand identification for G-protein-coupled receptors: A lead generation perspective. Curr Opin Chem Biol 2004; 8(3):287-96.
47. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov 2002; 1(11):882-94.
48. Bressi JC, Verlinde CL, Aronov AM et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem 2001; 44(13):2080-93.
49. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422(6928):198-207.
50. Tyers M, Mann M. From genomics to proteomics. Nature 2003; 422(6928):193-7.
51. Huber LA. Is proteomics heading in the wrong direction? Nat Rev Mol Cell Biol 2003; 4(1):74-80.
52. Kopec KK, Bozyczko-Coyne D, Williams M. Target identification and validation in drug discovery: The role of proteomics. Biochem Pharmacol 2005; 69(8):1133-9.
53. Moritz RL, Clippingdale AB, Kapp EA et al. Application of 2-D free-flow electrophoresis/RP-HPLC for proteomic analysis of human plasma depleted of multi high-abundance proteins. Proteomics 2005; 5(13):3402-13.
54. Tang HY, Ali-Khan N, Echan LA et al. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 2005; 5(13):3329-42.
55. Simpson DC, Smith RD. Combining capillary electrophoresis with mass spectrometry for applications in proteomics. Electrophoresis 2005; 26(7-8):1291-305.
56. Gongora R, Acestor N, Quadroni Met al. Mapping the proteome of Leishmania Viannia parasites using two-dimensional polyacrylamide gel electrophoresis and associated technologies. Biomedica 2003; 23(2):153-60.
57. Drummelsmith J, Brochu V, Girard Iet al. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol Cell Proteomics 2003; 2(3):146-55.
58. Drummelsmith J, Girard I, Trudel N et al. Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance. J Biol Chem 2004; 279(32):33273-80.
59. Gupta N, Goyal N, Rastogi AK. In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol 2001; 17(3):150-3.
60. Holzer TR, McMaster WR, Forney JD. Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana. Mol Biochem Parasitol 2006; 146(2):198-218.
61. Templin MF, Stoll D, Schrenk Met al. Protein microarray technology. Drug Discov Today 2002; 7(15):815-22.
62. Delehanty JB, Ligler FS. Method for printing functional protein microarrays. Biotechniques 2003; 34(2):380-5.
63. Gietz ID. Yeast two-hybrid system screening. Methods Mol Biol 2005; 313:345-72.
64. Ito T, Ota K, Kubota H et al. Roles for the two-hybrid system in exploration of the yeast protein interactome. Mol Cell Proteomics 2002; 1(8):561-6.
65. LaCount DJ, Vignali M, Chettier R et al. A protein interaction network of the malaria parasite Plasmodium falciparum. Nature 2005; 438(7064):103-7.
66. Rual JF, Venkatesan K, Hao T et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005; 437(7062):1173-8.
67. Suthram S, Sittler T, Ideker T. The Plasmodium protein network diverges from those of other eukaryotes. Nature 2005; 438(7064):108-12.
68. Crump A. New medicines from nature's armamentarium. Trends Parasitol 2006; 22(2):51-4.
69. Fournet A, Munoz V. Natural products as trypanocidal, antileishmanial and antimalarial drugs. Curr Top Med Chem 2002; 2(11):1215-37.
70. Okpekon T, Yolou S, Gleye C et al. Antiparasitic activities of medicinal plants used in Ivory Coast. J Ethnopharmacol 2004; 90(1):91-7.
71. Takahashi M, Fuchino H, Sekita S et al. In vitro leishmanicidal activity of some scarce natural products. Phytother Res 2004; 18(7):573-8.
72. Zhai L, Chen M, Blom Jet al. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother 1999; 43(6):793-803.
73. Panchal RG, Hermone AR, Nguyen TL et al. Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol 2004; 11 (1):67-72.
74. Zhou Y, Gregor VE, Sun Z et al. Structure-guided discovery of novel aminoglycoside mimetics as antibacterial translation inhibitors. Antimicrob Agents Chemother 2005; 49(12):4942-9.
75. Urbina JA. Chemotherapy of Chagas disease. Curr Pharm Des 2002; 8(4):287-95.
76. Urbina JA, Concepcion JL, Rangel Set al. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol Biochem Parasitol 2002; 125(1-2):35-45.
77. Fairlamb AH. Chemotherapy of human African trypanosomiasis: Current and future prospects. Trends Parasitol 2003; 19(11):488-94.
78. Fairlamb AH. Metabolic pathway analysis in trypanosomes and malaria parasites. Philos Trans R Soc Lond B Biol Sci 2002; 357(1417):101-7.
79. Linares GE, Ravaschino EL, Rodriguez JB. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr Med Chem 2006; 13(3):335-60.
80. Hunter WN, Alphey MS, Bond CS et al. Targeting metabolic pathways in microbial pathogens: Oxidative stress and anti-folate drug resistance in trypanosomatids. Biochem Soc Trans 2003; 31(Pt 3):607-10.
81. Robinson DR, Gull K. Basal body movements as a mechanism for mitochondrial genome segregation in the trypanosome cell cycle. Nature 1991; 352(6337):731-3.
82. Robinson DR, Sherwin T, Ploubidou A et al. Microtubule polarity and dynamics in the control of organelle positioning, segregation, and cytokinesis in the trypanosome cell cycle. J Cell Biol 1995; 128(6):1163-1172.
83. Ogbadoyi EO, Robinson DR, Gull K. A high-order trans-membrane structural linkage is responsible for mitochondrial genome positioning and segregation by flagellar basal bodies in trypanosomes. Mol Biol Cell 2003; 14(5):1769-79.
84. Broadhead R, Dawe HR, Farr H et al. Flagellar motility is required for the viability of the bloodstream trypanosome. Nature 2006; 440(7081):224-7.
85. Uboldi AD, Walsh P, Spurck T et al. A Leishmania mitochondrial protein determines cell morphology, mitochondrial segregation and virulence. 2006. 85b. Uboldi AD, Lueder FB, Walsh Pet al. A mitochondrial protein affects cell morphology, mitochondrial segregation and virulence in Leishmania. Int J Parasitol 2006; in press.
86. Ilgoutz SC, McConviUe MJ. Function and assembly of the Leishmania surface coat. Int J Parasitol 2001; 21:899-908.
87. Garami A, Ilg T. Disruption of mannose activation in Leishmania mexicana: GDP-mannose pyrophosphorylase is required for virulence, but not for viability. EMBO J 2001; 20(14):3657-3666.
88. Garami A, Ilg T. The role of phosphomannose isomerase in Leishmania mexicana glycoconjugate synthesis and virulence. J Biol Chem 2001; 276(9):6566-6575.
89. Garami A, Mehlert A, Ilg T. Glycosylation defects and virulence phenotypes of Leishmania mexicana phosphomannomutase and dolicholphosphate- mannose synthase gene deletion mutants. Mol Cell Biol 2001; 21(23):8168-8183.
90. Stewart J, Curtis J, Spurck TP et al. Characterisation of a Leishmania mexicana knockout lacking guanosine diphosphate-mannose pyrophosphorylase. Int J Parasitol 2005; 35(8):861-73.
91. Ralton JE, Nederer T, Piraino HL et al. Evidence that intracellular 131-2 mannan is a virulence factor in Leishmania parasites. J Biol Chem 2003; 278:40757-40763.
92. Collet JF, Stroobant V, Pirard Met al. A new class of phosphotransferases phosphorylated on an aspartate residue in an amino-terminal DXDX(T/V) motif. J Biol Chem 1998; 273(23):14107-12.
93. Koonin EV, Tatusov RL. Computer analysis of bacterial haloacid dehalogenases defines a large superfamily of hydrolases with diverse specificity. Application of an iterative approach to database search. J Mol Biol 1994; 244(1):125-32.
94. Kedzierski L, Malby RL, Smith BJ et al. Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms. J Mol Biol 2006; 363:215-27.
95. Silvaggi NR, Zhang C, Lu Z et al. The X-ray crystal structures of human alpha -phosphomannomutase 1 reveal the structural basis of carbohydrate defident glycoprotein syndrome type la, J Biol Chem 2006.
96. Warit S, Zhang N, Short A et al. Glycosylation deficiency phenotypes resulting from depletion of GDP- mannose pyrophosphorylase in two yeast species. Mol Microbiol 2000; 36(5):1156-66.
97. Davis AJ, Perugini MA, Smith BJ et al. Properties of GDP-mannose pyrophosphorylase, a critical enzyme and drug target in Leishmania mexicana. J Biol Chem 2004; 279(13):12462-12468.
98. Perugini MA, Griffin MD, Smith BJ et al. Insight into the self-association of key enzymes from pathogenic species. Eur Biophys J 2005; 34(5):469-476.
99. Perez-Montfort R, Gomez-Puyou MT, Gomez-Puyou A. The interfaces of oligomeric proteins as targets for drug design against enzymes from parasites. Curr Top Med Chem 2002; 2(5):457-70.
100. Chen DQ, Kolli BK, Yadava Net al. Episomal expression of specific sense and antisense mRNAs in Leishmania amazonensis: Modulation of gp63 level in promastigotes and their infection of macrophages in vitro. Infect Immun 2000; 68(1):80-6.
101. Zhang WW, Madashevski G. Loss of virulence in Leishmania donovani deficient in an amastigote specific protein A2. Proc Nad Acad Sci USA 1997; 94:8807-8811.
102. Flaspohler JA, Lemley K, Parsons M. A dominant negative mutation in the GIM1 gene of Leishmania donovani is responsible for defects in glycosomal protein localization. Mol Biochem Parasitol 1999; 99(1): 117-28.